Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Napsagatran Anhydrous SCHEMBL30693689 | 1.00 | F2 (0.76) | F2 | |
| Napsagatran Anhydrous SCHEMBL7294707 | 1.00 | F2 (0.76) | F2 | |
| Napsagatran Anhydrous SCHEMBL8947681 | 0.99 | F2 (0.76) | F2 | |
| Napsagatran Anhydrous SCHEMBL8947800 | 0.99 | F2 (0.76) | F2 | |
| Napsagatran Anhydrous SCHEMBL635609 | 0.99 | F2 (0.75) | F2 | |
| Napsagatran Anhydrous SCHEMBL8947631 | 0.99 | F2 (0.76) | F2 | |
| SCHEMBL7300991 | 0.98 | F2 (0.75) | F2 | |
| SCHEMBL7298126 | 0.97 | F2 (0.76) | F2 | |
| SCHEMBL7301035 | 0.92 | F2 (0.75) | F2 | |
| SCHEMBL8947770 | 0.92 | F2 (0.63) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | F2 1125/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | F2 314/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | F2 2849/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | F2 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.